Newron Pharmaceuticals SpA (FRA:NP5) Long-Term Debt: €0.00 Mil (As of Dec. 2025)


FRA:NP5 Newron Pharmaceuticals SpA FRA:NP5
64 GF Score
Price €12.65
GF Value €13.96
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Long-Term Debt?

Newron Pharmaceuticals SpA FRA:NP5 -0.78% 64 Long-Term Debt is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:NP5 with a GF Score™ of 64/100 and a GF Value™ of €13.96 (Fairly Valued). The stock has 5 warning signs investors should review.

Newron Pharmaceuticals SpA's Long-Term Debt for the quarter that ended in Dec. 2025 was €0.00 Mil.

Newron Pharmaceuticals SpA's quarterly Long-Term Debt declined from Dec. 2024 (€36.24 Mil) to Jun. 2025 (€18.06 Mil) and declined from Jun. 2025 (€18.06 Mil) to Dec. 2025 (€0.00 Mil).

Newron Pharmaceuticals SpA's annual Long-Term Debt increased from Dec. 2023 (€25.75 Mil) to Dec. 2024 (€36.24 Mil) but then declined from Dec. 2024 (€36.24 Mil) to Dec. 2025 (€0.00 Mil).

Newron Pharmaceuticals SpA  (FRA:NP5) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Newron Pharmaceuticals SpA Long-Term Debt Related Terms

Newron Pharmaceuticals SpA Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Long-Term Debt Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.54 45.17 25.75 36.24 0.00

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.75 48.53 36.24 18.06 0.00
FRA:NP5
64GF Score
Newron Pharmaceuticals SpA FRA:NP5
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €0.00 Mil mean?
Newron Pharmaceuticals SpA (FRA:NP5) has a Long-Term Debt of €0.00 Mil as of Dec. 2025.
Is Newron Pharmaceuticals SpA's Long-Term Debt too high?
Newron Pharmaceuticals SpA's current Long-Term Debt is €0.00 Mil. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Long-Term Debt compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Long-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Newron Pharmaceuticals SpA's current Long-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (FRA:NP5) is currently considered Fairly Valued. The stock's GF Value™ is €13.96, compared to a current price of €12.65 — trading 9.4% below its estimated fair value. The current Long-Term Debt is €0.00 Mil. Newron Pharmaceuticals SpA's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (FRA:NP5), the current Long-Term Debt is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €12.65 is trading 9.4% below its estimated GF Value™ of €13.96. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for FRA:NP5:

  • Long-Term Debt: €0.00 Mil
  • GF Value™: €13.96 vs. price of €12.65 (9.4% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score

Get the complete analysis for FRA:NP5

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.65
Price
€13.96
GF Value